|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Former Executive Chairman Paul Jacobs is considering a leveraged buyout, which would be incredibly expensive and face tough regulatory scrutiny.
Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
Let's see if Eli Lilly and Company (LLY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding ENDP is favorable, with net inflows of $15.68 billion.
Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.
South Dakota on Wednesday sued three major drugmakers, accusing them of deceptively marketing prescription opioids and contributing to a nationwide epidemic. Marty Jackley, the state's attorney general, announced civil claims against Purdue Pharma LP, a unit of Endo International Plc and Johnson & Johnson's Janssen unit. The lawsuit makes South Dakota at least the 16th U.S. state to sue manufacturers over opioids, which can be used to treat pain.